Ellenbarrie Share Price: Target 2026 to 2030, Valuation and Risks

Ellenbarrie Industrial Gases share price today

Anyone searching the Ellenbarrie share price in September 2026 is looking at a business that has been publicly quoted for barely over a year and has already travelled a range most established companies would take a decade to cover. The company itself is far older than its listing: Ellenbarrie Industrial Gases was incorporated in 1973, is headquartered in Kolkata and sells oxygen, nitrogen, argon, carbon dioxide and a long list of specialty and medical gases.

At the 10 September 2026 research cut-off, the completed-session price was approximately ₹346.50, market capitalisation about ₹4,894 crore and trailing EPS ₹9.44. That works out to roughly 36.7 times trailing earnings and 5.0 times a book value of ₹69.33 per share. The quote widget above can move after publication; every ratio and scenario input below stays fixed to the stated cut-off.

The tension in this stock is easy to state and hard to resolve. Industrial gases is one of the better business models in heavy industry, because a customer that takes oxygen through a pipe from a plant built on its own boundary does not switch supplier casually. Yet the reported return on capital employed is 15.2%, which is respectable rather than exceptional, and the shares carry a multiple that assumes the next phase of capacity building earns considerably more than the last one did.

What Ellenbarrie Industrial Gases actually sells

The company operates across five connected layers. It manufactures and supplies bulk industrial gases; it sells smaller-volume specialty and packaged gases; it supplies medical gases to hospitals; it designs and commissions the plants; and it installs medical gas pipelines and sells a small range of medical equipment. The published business description covers oxygen, nitrogen, argon, carbon dioxide, helium, acetylene, hydrogen, nitrous oxide, synthetic air and special gases on the industrial side, and medical oxygen, medical nitrogen, medical nitrous oxide and medical grade carbon dioxide on the healthcare side.

Business layer	Representative offering	Customer problem solved	Economic characteristic
Bulk industrial gases	Oxygen, nitrogen, argon, carbon dioxide	Continuous process input for steel, glass and chemicals	Contract-led, freight-bound, regional by nature
Specialty and packaged gases	Helium, acetylene, hydrogen, nitrous oxide, synthetic air	Smaller-volume and higher-specification needs	Better realisation per unit, more handling
Medical gases	Medical oxygen, nitrogen, nitrous oxide, carbon dioxide	Hospital life-support and clinical supply	Regulated, quality-audited, less cyclical
Project engineering	Design, supply, installation and commissioning of tonnage air separation units	Customers wanting captive on-site capacity	Lumpy revenue, execution risk, relationship-building
Medical gas pipelines and equipment	Pipeline systems, ventilators, sterilisation and lung-function systems	Hospital build-out and refurbishment	Project-shaped, tender-driven

The link between layers is what makes the model interesting. A company that designs and commissions cryogenic and non-cryogenic air separation plants can also install one next to a large customer and sell the output under a long supply contract. That is how gas businesses convert a one-off engineering job into an annuity. It is also why the balance sheet matters: the annuity is bought with capital spent years before the revenue arrives.

What moved the Ellenbarrie share price in the first year of listing

The shares changed hands between ₹180.50 and ₹551.90 over the trailing fifty-two weeks. At ₹346.50 the price sits 37.22% below that high and roughly 92% above that low. A band that wide across a single year is not unusual for a recently listed micro-cap with a limited float history, but it does mean any single-day quote is a poor guide to what the market has decided about the business.

Two readings taken five weeks apart make the point sharply. The figures below compare a Screener-derived set read on 5 August 2026 with the figures captured on 10 September 2026.

Measure	5 August 2026	10 September 2026
Market capitalisation	₹3,987 Cr	₹4,894 Cr
Trailing EPS	₹7.39	₹9.44
Price to earnings	38.19	36.71
Price to book	4.07	5.01
Book value per share	₹69.30	₹69.33
Distance from 52-week high	-47.1%	-37.22%

Market value rose about 23% in five weeks, and yet the earnings multiple fell, because the trailing EPS used in the denominator rose faster still. That is the mechanical signature of a fresh result being folded into the trailing twelve months. One caution belongs with it: the two EPS figures come from different data vendors and may not count exactly the same twelve months or the same treatment of exceptional items, so part of the move from ₹7.39 to ₹9.44 could be definitional rather than operational. Anyone using a multiple should know which earnings number sits underneath it, a point covered in the P/E ratio guide.

The reported financial record

Only two annual rows were captured for this name, both from Yahoo Finance, which labels a March financial year by the calendar year in which it ended. FY26 in the table below is the year ended March 2026.

Period	Revenue	Net profit	Reading
FY25 (year ended March 2025)	Not captured	₹83 Cr	Base year for the profit comparison
FY26 (year ended March 2026)	₹342 Cr	₹104 Cr	Profit up about 25% on FY25
Trailing twelve months to 10 Sep 2026	₹357 Cr	Not captured separately	Revenue running ahead of the FY26 total

Growth rates come from two different vintages and should be read as such.

Growth measure	Reading	Where it comes from
Five-year sales CAGR	14.29%	Screener-derived figures read on 5 August 2026
Five-year profit CAGR	34.13%	Screener-derived figures read on 5 August 2026
Revenue growth, year on year	18%	Yahoo Finance, most recent comparable period
Earnings growth, year on year	74.6%	Yahoo Finance, most recent comparable period

The 74.6% earnings-growth figure is not the FY26-over-FY25 comparison shown in the previous table, which is about 25%. Yahoo reports it as a most-recent-period growth rate and the captured data does not identify which period, so it should not be read as an annual figure.

The gap between a 14.3% sales CAGR and a 34.1% profit CAGR is the whole story of the last five years. Profit grew because margins expanded and because a larger share of volume moved through higher-value contracts, not because the company found a market growing at 34% a year. That distinction governs the forecast: an earnings line that outran sales by twenty percentage points a year cannot keep doing so indefinitely without the same expansion happening again, and margin expansion is a finite resource.

There is no quarterly profit and loss detail here. Only two quarterly revenue points were available and no quarterly profit line at all, which is far too thin to support a quarterly-results discussion. Rather than construct one, it is omitted. Anyone who wants to test the thesis properly should read the last two quarterly filings on the exchange, and the method for doing that quickly is set out in the guide to reading quarterly results.

Margins, returns and the gap between them

Measure	Reading	What it says
Operating margin, Screener-derived	34.02%	Strong for a manufacturing business
Operating margin, Yahoo basis	31.76%	Same story, different definition
Net profit margin	33.83%	Sits above the 31.76% Yahoo-basis operating margin
Return on equity	14.20%	Ordinary against the price paid for equity
Return on capital employed	15.23%	Capital intensity caps the return
Five-year average ROCE	15.11%	Remarkably steady through the growth phase
Dividend yield	0.00%	The case rests entirely on reinvestment

Two things in that table deserve a second look. The first is that net profit margin of 33.83% is higher than the operating margin of 31.76%. Operating profit is what the gas business earns; anything that lifts the bottom line above it is coming from outside operations, such as other income on cash raised, or from tax and accounting effects. Investors should want to see how much of reported profit is operating profit before extrapolating the earnings growth rate.

The second is the stability of ROCE. A five-year average of 15.11% against a current 15.23% says the company has added capacity without diluting its returns, which is genuinely creditable. But it also says the returns have not improved with scale. A 34% operating margin that converts into a 15% return on capital is telling you exactly how much steel, cryogenic tankage and distribution the model requires per rupee of profit. The return on equity guide explains why a high margin and a modest return ratio can coexist.

The balance sheet behind the annuity

Item	Reading	Note
Total debt	₹184 Cr	Modest against a ₹4,894 Cr market value
Cash and equivalents	₹84 Cr	Leaves roughly ₹100 Cr of net debt
Debt to equity	18.87%	Low gearing for a capital-intensive industry
Promoter holding	77.76%	Very high; the free float is correspondingly thin
Promoter shares pledged	0%	No pledge reported

Low leverage is a real advantage in this industry, because an air separation unit built with debt against a customer that later reduces offtake is how gas companies get hurt. A debt-to-equity ratio under 20% leaves room to fund the next plant without a rights issue, though it does not promise that no equity will be raised.

The 77.76% promoter holding cuts both ways. It aligns the controlling family with minority shareholders and signals no intent to sell down, but it leaves a small tradable float, which is part of why the price has covered a three-times range in twelve months. Thin floats amplify both re-rating and de-rating.

Why industrial gases can behave like an annuity

The economics of the sector are unusual. Gases are expensive to transport relative to their value, so supply is regional and a plant near a customer has a structural cost advantage over one three hundred kilometres away. Large customers in steel, glass, chemicals and healthcare cannot pause consumption without pausing production. On-site and pipeline arrangements typically run for years, which converts a capital project into a long revenue stream.

Ellenbarrie’s position in eastern India fits that logic. The industrial base there is heavy on steel and metals, which are among the largest oxygen consumers in any economy, and healthcare demand for medical gases has expanded across the whole country. The company also builds the plants, which gives it a route into new customers that a pure distributor does not have.

None of this makes the business immune. Regional advantage is a moat only where the company holds the region. Gas demand is directly tied to the utilisation of customer plants, so a steel downturn shows up in volumes with little lag. And the project engineering line, which helps win contracts, is lumpy and carries the usual execution and receivables risk of any capital-goods work.

Valuation at the research cut-off

Valuation measure	Reading	Interpretation
Completed-session price	₹346.50	Fixed research input, not a live figure
Market capitalisation	₹4,894 Cr	Micro-cap; liquidity and disclosure depth both matter
Trailing EPS	₹9.44	Yahoo Finance trailing basis
Recalculated P/E	36.71	Price divided by trailing EPS
Reported P/E	36.78	Same measure, vendor calculation
Book value per share	₹69.33	Implies price to book of 5.01
EBITDA, trailing basis	₹124 Cr	Roughly a third of ₹357 Cr trailing revenue
EV/EBITDA	24.65	Screener-derived, 5 August 2026; not recomputed on the 10 September market cap
PEG	1.12	Screener-derived, 5 August 2026
ROCE / ROE	15.23% / 14.20%	Screener-derived, 5 August 2026; below what a 36-times multiple usually implies

Three of those rows carry the earlier vintage, and the EV/EBITDA line is the one to be careful with. On the 10 September inputs printed above — a ₹4,894 Cr market value plus ₹184 Cr of debt less ₹84 Cr of cash, against ₹124 Cr of trailing EBITDA — the enterprise multiple would be about 40 times, not 24.65. The lower figure belongs to the 5 August reading, when the market value was ₹3,987 Cr.

A PEG of 1.12 looks reasonable until you notice which growth rate produced it. That PEG was struck against the 5 August P/E of 38.19; divide it by 1.12 and the implied growth is 34.1%, which is the five-year profit CAGR of 34.13% almost exactly. In other words, the multiple is only comfortable if the historical earnings pace repeats. Every scenario below deliberately assumes it will not, and the method behind that choice is described in the stock valuation guide.

Valuation framework

The scenario model starts with TTM EPS of ₹9.44. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹5. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded, which costs nothing here because the yield is zero.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	10%	22×	Volume growth tracks eastern-India industrial demand, margin expansion stops and the listing premium fades
Base	16%	32×	New capacity fills at current margins and the post-listing premium settles back modestly
Bull	22%	42×	On-site contracts and medical gases scale together, returns on capital improve and the rating expands modestly

The multiple range is set below to modestly above the current 36.71. The bear case assumes a de-rating to 22 times, which is what happens when a recently listed capital-intensive company delivers ordinary growth. The bull case allows 42 times, above the present rating but not dramatically so, because assuming both perfect execution and permanent multiple expansion would be a way of writing today’s optimism into the future twice. None of the growth rates reaches the 34.13% of the last five years.

Ellenbarrie Industrial Gases share price target 2026 to 2030

The grid above is generated only from the disclosed EPS, growth and exit multiple inputs. It does not model a fresh equity issue, a large debt-funded plant, a change in the promoter stake, exceptional items, the loss or gain of a single large offtake contract, or any change in the mix between gas supply and project engineering. It also cannot know how much of the current trailing EPS is operating profit. These are arithmetic scenarios, not probability-weighted forecasts, and they should be rebuilt after each result.

Risks that can break the thesis

The starting valuation is the first risk. At 36.7 times trailing earnings and 5.0 times book, a good deal of future growth is already in the price, and earnings can rise for years while the shares go nowhere if the multiple compresses. That is not a hypothetical for this stock: it already trades 37.22% below its own 52-week high.

The second is customer concentration by industry. Bulk gas volumes follow the utilisation of steel, metals and chemical plants. A regional industrial slowdown reduces offtake immediately, and the fixed costs of an air separation unit do not fall with it.

The third is the short public record. The shares listed in June 2025, so there is roughly a year of filings, one annual report cycle as a listed company and no history of how management guides, discloses or handles a bad quarter. The five-year CAGRs describe a private company’s trajectory, and private-company growth rates are not always achieved again under public-market capital discipline.

Add to those the ordinary hazards: project execution and receivables in the engineering line, safety and regulatory compliance in medical gases, helium and other bought-in gases whose supply is globally tight, and a thin free float that can move the price on modest volume. There is no dividend to cushion any of it.

What would change the thesis

The case strengthens if ROCE moves clearly above the 15.11% five-year average while capacity expands, if operating profit rather than other income drives the earnings growth, and if new on-site contracts are disclosed with enough detail to show the revenue is contracted rather than spot. Steady conversion of profit into operating cash flow, with debt to equity staying near current levels through the build-out, would confirm that the annuity model is working as advertised.

It weakens if margins slip while revenue grows, if the gap between net profit margin and operating margin widens further, if project revenue starts to dominate the mix and brings its lumpiness with it, or if the company funds its next phase with equity at a lower price. A sustained fall in eastern-India steel output would show up in volumes before it showed up in the narrative.

Monitoring scorecard

Question	Constructive evidence	Warning sign
Is profit operating profit?	Operating profit grows in line with net profit	Net margin keeps exceeding operating margin
Is new capacity earning?	ROCE rises above 15.2% as plants commission	Capital employed grows while ROCE drifts down
Is the revenue contracted?	Long-term on-site and pipeline agreements disclosed	Growth explained only by project wins
Is the balance sheet intact?	Debt to equity stays near 19% through capex	Fresh equity raised or gearing steps up
Is disclosure improving?	Segment split between gases and engineering	Consolidated numbers with no breakdown
Is the promoter stake stable?	77.76% holding maintained, no pledge	Stake reduction or any pledging appears

What to weigh at the current price

Ellenbarrie sits in a sector with genuinely attractive characteristics. A 34% operating margin, a five-year profit CAGR of 34.13%, no pledged promoter shares and debt to equity under 20% describe a well-run business rather than a speculative one. Eastern India is a sensible place to own gas capacity, and the ability to build the plants as well as supply the gas is a real commercial advantage.

What the price already assumes is the harder question. A 36.7 times multiple on trailing earnings, backed by a 15.2% return on capital and no dividend, requires the next five years to look like the last five, which in turn required margin expansion that cannot repeat indefinitely. The information needed to test that is not another capacity announcement but a full set of statements showing where the profit comes from, how much of the revenue is contracted, and whether the return on capital rises as the newest plants reach full utilisation. Until those are on the table, this is a business worth following closely with a small evidence base.

FAQ

What is the Ellenbarrie Industrial Gases share price target for 2026?

The 2026 line in the scenario grid is generated from trailing EPS of ₹9.44, an assumed annual growth rate and an exit multiple, compounded for only the 112 days remaining in the calendar year from the 10 September research cut-off. It is a range of arithmetic outcomes under stated assumptions, not a forecast of where the price will be, and it changes whenever trailing EPS is restated.

What is the Ellenbarrie share price target for 2030?

The 2030 line applies the same three growth rates and exit multiples over four more years of compounding, which is why the gap between the low and high scenarios widens so much. Small differences in assumed growth become large differences in outcome over five years. Treat the spread as a measure of uncertainty rather than a prediction.

What does Ellenbarrie Industrial Gases do?

It manufactures and supplies industrial gases such as oxygen, nitrogen, argon, carbon dioxide, helium, acetylene and hydrogen, along with medical gases for hospitals. It also designs, supplies and commissions tonnage air separation units, builds cryogenic and non-cryogenic plants, installs medical gas pipeline systems and sells medical equipment including ventilators and sterilisation systems. The company was incorporated in 1973 and is based in Kolkata.

When did Ellenbarrie Industrial Gases list on the exchange?

The shares listed in June 2025, giving the company a public record of a little over a year at the time of writing. The issue price is not among the figures captured for this article, so it should be read from the exchange’s own record rather than taken from any secondary summary. The NSE quote page linked below carries the listing and filing history.

What is the ROCE of Ellenbarrie Industrial Gases?

Return on capital employed was 15.23%, against a five-year average of 15.11%. Return on equity was 14.20%. The consistency between the current figure and the five-year average suggests the company has grown without diluting its returns, although it also means scale has not yet improved them.

Who are the promoters of Ellenbarrie Industrial Gases?

Promoter holding stood at 77.76% with no shares pledged. That is a high level of control, which aligns the promoters with other shareholders but leaves a small free float, and a thin float is one reason the share has traded between ₹180.50 and ₹551.90 in twelve months.

Related research

• INOX India share price target
• Kronox Lab Sciences share price target
• Navin Fluorine share price target
• How to value a stock: the method behind these scenarios
• P/E ratio formula and what it actually measures
• Return on equity explained
• Debt-to-equity ratio: formula and meaning
• How to read quarterly results in 15 minutes

Sources and methodology

• Ellenbarrie Industrial Gases on Screener.in
• Ellenbarrie Industrial Gases quote and filings on NSE
• Ellenbarrie Industrial Gases company website

Price, 52-week range, market capitalisation, trailing EPS, book value, debt, cash, EBITDA, the annual revenue and profit rows and the year-on-year growth figures were captured from Yahoo Finance after the completed 10 September 2026 session. The operating margin, return on equity, return on capital employed, the five-year average ROCE, the five-year sales and profit CAGRs, PEG, EV/EBITDA and promoter holding come from Screener-derived figures read on 5 August 2026, which is why the two vintages are labelled separately wherever they appear together. Screener’s full multi-year financial statements were not captured for this name, so no quarterly results section appears. The company description comes from the published business summary. The scenario engine uses the formula and partial-year convention disclosed above, and the live quote does not recalculate it. Everything beyond those figures, including the growth and exit-multiple choices, the reading of the margin gap and the assessment of float and concentration risk, is analytical judgment.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.